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AbsTrACT
Various theories about drugs such as ACE inhibitors or 
angiotensin II receptor blockers (ARBs) in relation to 
severe acute respiratory syndrome coronavirus 2 (SARS- 
CoV-2) and clinical outcomes of COVID-19 are circulating 
in both mainstream media and medical literature. 
These are based on the fact that ACE2 facilitates SARS- 
CoV-2 cell invasion via binding of a viral spike protein 
to ACE2. However, the effect of ACE inhibitors, ARBs 
and other drugs on ACE2 is unclear and all theories 
are based on conflicting evidence mainly from animal 
studies. Therefore, clinical evidence is urgently needed. 
The aim of this study is to investigate the relationship 
between use of these drugs on clinical outcome of 
patients with COVID-19. Patients will be included from 
several hospitals in Europe. Data will be collected in a 
user- friendly database (Digitalis) on an external server. 
Analyses will be adjusted for sex, age and presence of 
cardiovascular disease, hypertension and diabetes. These 
results will enable more rational choices for randomised 
controlled trials for preventive and therapeutic strategies 
in COVID-19.
InTroduCTIon
Understanding the pathophysiology of the 
COVID-19 pandemic is key to develop strategies for 
both prevention and treatment to improve clinical 
outcomes. It is known from the previous outbreak 
of severe acute respiratory syndrome coronavirus 
(SARS- CoV) that cell invasion is accomplished by 
binding of a viral spike protein to ACE2.1 Recent 
reports show that this is the same for SARS- CoV-2.2 3 
This binding leads to ACE2 downregulation, which 
may contribute to lung injury, since less ACE2 is 
available for potential protective effects, as shown 
in acute respiratory distress syndrome (ARDS).4
ACEs are regulatory proteins in both blood pres-
sure and inflammation. ACE1, the key enzyme in 
the renin–angiotensin aldosterone system (RAAS), 
converts angiotensin I to angiotensin II which by 
binding to the angiotensin II receptor type 1 leads 
to vasoconstriction, resulting in a rise of blood 
pressure, fibrotic and proliferative/inflammatory 
effects. ACE1 is targeted for reducing blood pres-
sure by ACE inhibitors; angiotensin II receptor 
blockers (ARBs) lead to similar effects by blocking 
the effects of angiotensin II.
ACE2 degrades angiotensin I to angiotensin-(1-9) 
and angiotensin II to angiotensin-(1-7)(4). This 
pathway involving the Mas receptor is thought 
to be counteracting the effects of angiotensin II 
and is associated with protective effects for heart, 
lungs and kidneys.5 However, studies targeting this 
pathway have not led to beneficial effects in cardio-
vascular and renal diseases including hyperten-
sion.6 7 In addition to its role in RAAS modulation, 
ACE2 is also involved in degrading several other 
substrates, such as apelin, bradykinin and opioids. 
Recently, involvement in degrading bradykinin has 
also been suggested as playing a causal role in the 
development of severe ARDS, since downregula-
tion of ACE2 as a consequence of virus binding may 
enhance the proinflammatory bradykinin receptor 
leading to local vascular leakage.8
The fact that patients with previous cardiovascular 
disease (CVD), hypertension and diabetes have an 
increased mortality risk due to SARS- CoV-2- induced 
infection could be explained by the common factor of 
use of ACE inhibitors or ARBs.9 10 This was suggested 
by several authors and also reached the mainstream 
media including CNN.11 12 However, well- designed 
studies on the effects of ACE inhibitors, ARBs and 
non- steroidal anti- inflammatory drugs on ACE2 
expression are scarce, show conflicting results and 
have not been conducted in humans.6 13–15 This has 
led to statements from several societies, including 
the European Society of Cardiology and the Euro-
pean Society of Hypertension, emphasising the lack 
of evidence and the importance of not withdrawing 
ACE inhibitors and ARBs considering their major role 
in blood pressure lowering, nephroprotection and 
cardiac protection.5 In reply to these first rumours, 
other authors, including Versmissen et al, argued 
that RAAS inhibition might even be beneficial once 
infected.16–18 Other authors suggested that ARBs 
might be beneficial while ACE inhibitors might not.19
Based on these theoretical grounds, intervention 
studies, either starting or discontinuing ACE inhib-
itors or ARBs, are currently recruiting patients with 
COVID-19 ( ClinicalTrials. gov). However, obser-
vational data in humans are urgently needed to 
address the real effect of medication and the clin-
ical course of COVID-19 before starting potentially 
harmful interventions based on only theoretical and 
conflicting evidence from animal studies. Therefore, 
the COMET study aims to evaluate the relationship 
between use of certain drugs, starting with ACE inhib-
itors and ARBs, on clinical outcomes of patients with 
COVID-19. The main objective is to describe the 
correlation between use of ACE inhibitors or ARBs 
and clinical outcome, defined by admission to the 
hospital, duration of stay, intensive care unit (ICU) 
admission and survival, in patients with confirmed 
COVID-19. Secondary aims are to address the effect 
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of other drugs, such as immunomodulatory agents, including non- 
steroidal anti- inflammatory drugs and corticosteroids.
MeThods And AnAlysIs
An observational cohort study has been designed. Patients will be 
included from various hospitals in Europe by a pharmacist, clinical 
pharmacologist or treating physician. The participating investiga-
tors are asked to consecutively include all patients registered at the 
emergency department (ED) on a certain day or several days until 
a minimum of 50 patients have been included. If ED registration 
is incomplete, all patients with COVID-19 who are hospitalised 
during a specific period until a minimum of 50 patients has been 
reached (both ICU and normal ward) will be entered. The major 
criterion for a patient to be included is COVID-19 positive by a 
positive SARS- CoV-2 PCR or high clinical likelihood based on 
bilateral pulmonary infiltrates not explained by another cause or 
after consensus of the local COVID-19 expert team based on clin-
ical, biochemical and radiological criteria.
data collection
To allow urgent analysis, data entry will be undertaken in two 
phases. For quick data entry, the number of collected parameters 
will be minimised and with a special focus on medication. The 
following subject parameters will be collected for all patients: 
year of birth, sex, International Classification of Primary Care/In-
ternational Classification of Diseases, 10th Revision medical 
history including CVD, diabetes, hypertension, body mass index 
(normal 20–25 kg/m2, high 25–30 kg/m2 or obese >30 kg/m2), 
prescribed medication by Anatomical Therapeutic Chemical code 
and dose (at moment of presentation), smoking history, clinical 
frailty score,20 logistic course (presentation at ED/transmission 
from/to another hospital), clinical course (no admission/admission 
to hospital <48 hours/>48 hours, no ICU, admission ICU) and 
survival. If easily accessible, laboratory data at presentation will 
also be entered. In the second phase, additional parameters may 
be included such as more specific clinical outcomes such as pulmo-
nary embolism or more extensive laboratory parameters.
definitions and clinical outcomes
Since the medical history may be incomplete at the ED as recorded 
by the collaborating researchers, medication data will be used 
to confirm CVD, diabetes, heart failure and hypertension or to 
correct when medical history appears to be incomplete. CVD, 
including coronary artery disease, cerebrovascular disease and 
peripheral arterial occlusive disease, will be considered present 
when entered as items in the medical history and when a patient 
is using antiplatelet therapy to prevent bias of misdiagnosed CVD, 
especially in the case of angina.
Diabetes will be considered present when antidiabetic medica-
tion is used, even in the absence of a note in the medical file, to 
prevent bias of undiagnosed diabetes. Hypertension will be consid-
ered present when entered as an item in the medical history and 
antihypertensive medication is used or when a patient is using one 
or more antihypertensive drugs without other indication. Heart 
failure will be considered present when entered as an item in the 
medical history or when a patient is using an ACE inhibitor or 
ARB, a beta blocker and a loop diuretic in the absence of severe 
renal insufficiency.
outcome
Clinical outcome will be assessed during 2 weeks after the date of 
COVID-19 diagnosis, and scored as no hospital admission, hospital 
admission <48 hours, hospital admission >48 hours without ICU, 
hospital admission >48 hours with ICU. In addition, survival data 
will be collected.
data analysis
The relation between ACE inhibitors/ARBs and clinical outcomes 
will first be assessed by univariate and multivariate logistic regres-
sion analyses. Adjustments will be made for the following poten-
tial confounding factors: sex, age and presence of CVD, diabetes 
and hypertension. A dose–response analysis will be performed to 
support a causal relationship.
Since only patients visiting the ED will be included, they might 
not be representative for the larger population not visiting the 
hospital. Therefore, the aim is to compare the use of ACE inhibi-
tors/ARBs in the Dutch patients with the general Dutch population 
of similar age (age group of 10 years; Stichting Farmaceutische 
Kengetallen: foundation pharmaceutical key numbers). In addi-
tion, use of other blood pressure- lowering agents and other drug 
classes such as lipid- lowering drugs will be compared between 
patients with most severe outcomes and no hospital admission or a 
short stay (<48 hours).
eThICs And dIsseMInATIon
The medical ethical committee of Erasmus MC and Brabant 
concluded this research does not fall under the scope of the Medical 
Research Involving Human Subjects Act (non- WMO) because of 
its retrospective nature and full anonymisation. Investigators from 
each hospital will fill in anonymised data (sex and birth year) and 
all will sign a data transfer agreement. Each patient will be assigned 
a study number known only by the investigator who will keep a 
coding list in the own hospital. Each hospital can only see their own 
patients in the system. Data will be collected in a database ( digitalis. 
nl) on an external server and then stored using Open Clinica. All 
data will be treated according to the privacy regulations applicable 
for Europe and the Erasmus MC privacy regulations. Collected 
data will be secured against unauthorised access and will be stored 
and secured by the department of Hospital Pharmacy. No data that 
can identify a patient will be processed on this database to protect 
and respect the privacy of all patients. The main research team 
including the principal investigator can see all anonymised data. 
The main article will be submitted to a general medicine journal; 
follow- up articles focusing more deeply on certain drug classes 
might be submitted to pharmacological journals or journals in the 
specific area of disease, for instance cardiovascular.
dIsCussIon
Currently, clinical trials targeting ACE2, RAAS and the bradykinin 
pathway are initiated while the evidence that this might be benefi-
cial is still weak. The results of this study may contribute to more 
rational choices for randomised controlled trials. In addition, when 
any negative effect of use of ACE inhibitors or ARBs is identified, 
changing medication might be an easy intervention to reduce 
morbidity and mortality from COVID-19. For instance ACE inhib-
itors and ARBs are used by over 10% of the Dutch population ( 
gipdatabank. nl); almost half of these users are aged above 70 years.
The most serious limitation of this study is the selection bias, 
especially when ED registration of unhospitalised patients is 
incomplete. However, for comparing ACE inhibitors and ARBs the 
indications are similar preventing a bias by indication; in addition, 
other antihypertensive drugs and lipid- lowering drugs will be anal-
ysed. Due to the urgency of need of this data, time to enter clinical 
data will be limited, potentially leading to incomplete data, espe-
cially the medical history. However, by using detailed medication 
data this can largely correct for incomplete medical history data.
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